9:25 am Chairperson’s Opening Remarks

Analyzing How to Marry Your Linker-Payload to Your Target For a Maximized Therapeutic Index

9:30 am The Vital Triad of ADC Design: Target, Indication & Payload

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics


  • Reviewing how the selection of an ADC target requires consideration of the potential clinical indications and the mechanistic properties of available linker payloads
  • Assessing how the availability of novel differentiated linker-payloads provides an opportunity to calibrate potential clinical success against validated clinical benchmarks
  • Presenting case study examples to demonstrate integration of target selection, clinical indication options and payload MoA

10:00 am Tubutecan Platform: Technology-enabled Payload Solutions Targeting Topoisomerase-I

  • Annette Vogl Director, Biology & Translational Research, Tubulis GmbH


  • Understand how Tubulis’ P5-conjugation technology enabled rapid generation of stably linked, hydrophilic DAR8 ADCs from native antibodies
  • Topoisomerase-I-inhibitors have become a promising payload class for ADCs in solid tumors. Tubutecans are a novel linker-payload platform for ADCs enabling the efficient and steady delivery of the TOPO-I-targeting payloads to the malignant cells
  • Evaluate how the implementation of an in vitro screen for on-target/off-tumor effects aids in designing the optimal combination of linker-payload and DAR matched with target properties

10:30 am Discussing How to Successfully Design & Develop Your Antibody-Drug Conjugate

10:45 am
Speed Networking Break


This session is an opportunity to connect with peers working in target selection and hold indepth conversations with some of the brightest minds working in the ADC field to establish meaningful and lasting relationships.

11:45 am Pairing Zymeworks’ Topoisomerase 1-inhibitor Linker-Payload with the Appropriate ADC Target, Antigen, & Indication


  • Zymeworks is focused on applying its ADC technologies for the treatment of patients suffering from diseases with high unmet need
  • Integrated consideration of the antibody, linker-payload, indication, and target compatibility are important in the design of antibody drug conjugates
  • Factors considered in the design of Zymeworks’ Topoisomerase 1-inhibitor ADC candidates ZW191, ZW220 and ZW251 will be reviewed

12:15 pm Building an ADC: What are the Key Characteristics You Need to Select For With Target in Mind


  • Examining the key characteristics that influenced the matching of the specific payload to the specific target
  • Providing a case study of a METxMET Bispecific ADC for NSCLC
  • Exploring how the METxMET ADC could potentially be effective in a larger population of lung cancer patients than MET blockers

12:45 pm Utilizing Reverse Immunology for ADC Target Discovery

1:00 pm
Lunch & Networking

Express Yourself – Examining the Importance of Expression Profile

2:00 pm Targeted Cancer Therapy for Patients With 17p Deletion

  • Anikó Pálfi Director, Biochemistry & Cell Biology, Heidelberg Pharma Research GmbH


  • Discussing Del(17p) as a potential platform-wide predictive biomarker for amanitin based ADCs
  • Highlighting superior efficacy of amanitin based ADCs in cancer models with 17p loss
  • Outlining the expedited clinical development of HDP-101 for Del(17p) patients

2:30 pm Computational Pathology – the Next Revolution in Companion Diagnostics

  • Mark Gustavson Senior Director, Oncology Translational Medicine, AstraZeneca


  • IHC is commonly used to measure target levels of ADCs despite the fact that it is
  • Sharing a method developed using image analysis and computational methods
    to score membrane targets with a continuous quantitative manner
  • This method enables target expression per cell to be measured and allows for
    the modelling of bystander effects

3:00 pm
Afternoon Break

3:30 pm Panel Discussion – Thinking Strategically About What Targets You Select

  • Robert Lutz Chief Scientific Officer, Iksuda Therapeutics
  • Annette Vogl Director, Biology & Translational Research, Tubulis GmbH
  • Yu Shen Director, Oncology Discovery, AbbVie
  • Hanspeter Gerber Chief Scientific Officer, Codeable Therapeutics


  • Understanding where your target choice and ADC fits into the ADC and wider oncology landscape?
  • How do you differentiate yourself through using improved linker-payload technologies on previously validated targets?
  • Balancing risk in your pipeline through your target choice
  • Novel targets or previously validated targets?
  • Discussing the role of future HER2 ADCs

4:15 pm Chairperson’s Closing Remarks

4:30 pm Scientific Poster Session


While the formal presentations of Day One come to an end, the learning doesn’t stop as we enter the Scientific Poster Session. This will serve as the perfect opportunity to showcase your recent work to your peers and allow you to learn and share insights in a relaxed atmosphere.

5:30 pm End of Conference Day One